Cardinal Health, Inc.

Cardinal Health, Inc.

CAH

$253.77

Updated: 03/11/2026, 15:31:13

Market Cap
$58.76B
Sector
Healthcare
Industry
Medical - Distribution
Country
US

No historical data available

Company Profile

Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.

USD
NYSE
CEO: Jason Hollar
Employees: 61,344
https://www.cardinalhealth.com
Asset Summaries
Latest generated summaries for CAH

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
CAH-10-k-fy2026.html2.8 MBtext/htmlENFiled 11/08/2026Period ended 30/06/2026

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2026 filing.

Evidence-backed · 44 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.7B

FY 2026 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$4.5B

FY 2026 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$1.4B

FY 2026 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Pharma segment activities
GMPD segment activities
Specialty pharmaceuticals and plasma products
GMPD product lines

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global healthcare services and products company

98%
Source evidence
“Cardinal Health, Inc. is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.”

Company overview

Global healthcare services and products company serving hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical labs, physician offices, and home patients

98%
Source evidence
“is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home”

Company overview

Global healthcare services and products company providing pharmaceuticals and medical products and supply chain solutions

98%
Source evidence
“Cardinal Health, Inc. is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices.”

Reportable segments

Two reportable segments: Pharma and GMPD; Other includes Nuclear and Precision Health Solutions, at-Home Solutions, OptiFreight Logistics

98%
Source evidence
“We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment.”

Reportable segments

Two reportable segments: Pharma and GMPD; Other includes Nuclear and Precision Health Solutions, at-Home Solutions, OptiFreight Logistics

98%
Source evidence
“We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment.”

GMPD segment

Global Medical Products and Distribution (GMPD) segment

97%
Source evidence
“Our GMPD segment manufactures and sources Cardinal Health branded general and specialty medical, surgical, and laboratory products and devices.”

Customer categories

Serves hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices

97%
Source evidence
“providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices”

Customer categories

Retail pharmacies, hospitals, providers, pharma manufacturers

95%
Source evidence
“distributes branded and generic pharmaceutical and over-the-counter healthcare and consumer products to retailers (including chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers), hospitals, and other healthcare providers”

Pharma segment activities

US distribution of branded/generic/specialty/OTC products; manufacturer services; pharmacy management; repackaging; MSO platforms

97%
Source evidence
“distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States”

GMPD segment activities

Cardinal Health brand and national brand medical/surgical/lab products sold in US, Canada, Europe, Asia

96%
Source evidence
“manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets”

Specialty pharmaceuticals and plasma products

Specialty pharmaceuticals incl. oncology, rheumatology, plasma products

95%
Source evidence
“Specialty pharmaceutical products include oncology, rheumatology, gastroenterology, urology, nephrology, and other pharmaceutical products.”

GMPD product lines

Cardinal Health branded medical, surgical, laboratory products

95%
Source evidence
“These products include exam and surgical gloves; needle, syringe, and sharps disposal; compression; incontinence; nutritional delivery; wound care; single-use surgical drapes, gowns, and apparel”

Segment profit disclosure reference

Pharma segment financials in Note 13 (fiscal 2026, 2025, 2024)

85%
Source evidence
“See Note 13 of the "Notes to Consolidated Financial Statements" for Pharma segment revenue, profit, and assets for fiscal 2026, 2025, and 2024.”

Operations and dependencies

Direct commodity exposure

$457M forecasted commodity exposure; 10% move = $46M impact

95%
Source evidence
“Our forecasted direct commodity exposures for the upcoming fiscal year is $457 million. The potential gain/loss for fiscal 2026, given a hypothetical 10 percent fluctuation in commodity prices”

FX exposure and VAR

15 principal currencies; transactional VAR $15M, translational VAR $2M

95%
Source evidence
“the potential maximum loss in earnings for the upcoming fiscal year is estimated to be $15 million, which is based on a one-year horizon and a 95 percent confidence level.”

Red Oak Sourcing venture with CVS Health

Red Oak Sourcing generic sourcing venture with CVS Health through June 2029

98%
Source evidence
“Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health, negotiates generic pharmaceutical supply contracts on behalf of both companies. The term of Red Oak Sourcing extends through June 2029.”

Positioning and strategy

Fiscal 2026 Specialty Alliance acquisition of Solaris Health

In fiscal 2026, the Specialty Alliance completed several acquisitions, including Solaris Health

97%
Source evidence
“In fiscal 2026, the Specialty Alliance completed several acquisitions, including the acquisition of Solaris Health.”

Fiscal 2025 acquisitions

Fiscal 2025: Integrated Oncology Network and GI Alliance (Specialty); Advanced Diabetes Supply Group (At-Home)

97%
Source evidence
“in fiscal 2025, we completed several acquisitions in disparate businesses: the acquisition of Integrated Oncology Network and GI Alliance, which are part of our Specialty business, and the acquisition of Advanced Diabetes Supply Group, which is part of our Cardinal Health At-Home businesses.”

Solaris Health acquisition

Completed acquisition of Solaris Health, a urology MSO, for ~$1.9B cash on November 3, 2025 via The Specialty Alliance

96%
Source evidence
“we, through The Specialty Alliance, completed the acquisition of Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash”

Capital expenditures and FY2027 expectation

Capex $649M FY2026 vs $547M FY2025; ~$700M expected FY2027 for manufacturing/distribution infrastructure and technology

95%
Source evidence
“We expect capital expenditures in fiscal 2027 to be approximately $700 million and primarily related to manufacturing and distribution infrastructure projects and technology investments.”

Generic pharmaceutical margin dynamics

Generic margins highest post-launch then decline; branded fees tied to WAC

90%
Source evidence
“Our earnings on generic pharmaceuticals are generally highest during the period immediately following the initial launch of a product, because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time.”

MSO growth strategy

MSO acquisition-driven growth providing physician practice support and management services

93%
Source evidence
“Since fiscal 2025, we have completed a number of acquisitions to establish and grow our MSO businesses. Through our MSO businesses, we provide physician practice support and management services that complement our legacy businesses.”

Risks, financing, and outlook

Total long-term obligations

Total long-term obligations including current portion and short-term borrowings of $8.9 billion at June 30, 2026

97%
Source evidence
“At June 30, 2026, we had total long-term obligations, including the current portion and other short-term borrowings, of $8.9 billion.”

Debt repayment activity FY2026

Repaid $500M 3.75% Notes at maturity and prepaid $100M of Floating Rate Term Loan due 2028 in FY2026

94%
Source evidence
“we repaid the full principal of $500 million of the 3.75% Notes due 2025 at maturity with available cash and we made a partial principal prepayment of $100 million for the Floating Rate Term Loan due 2028”

Fiscal 2026 goodwill impairment

$184 million pre-tax goodwill impairment charge to Navista & ION reporting unit in fiscal 2026

99%
Source evidence
“we recorded a pre-tax goodwill impairment charge of $184 million to our Navista & ION reporting unit.”

Impairment of Outcomes equity interest

FY2026 impairment of equity interest in Outcomes of $122M

95%
Source evidence
“Impairment of equity interest in Outcomes122 — —”

Contractual obligations table

Total contractual obligations $20,607M: debt $8,690M; interest $4,198M; finance leases $213M; operating leases $1,280M; purchase obligations $2,006M; opioid settlements $4,220M

95%
Source evidence
“Total contractual obligations and cash requirements (7) $3,698 $3,676 $3,360 $9,873 $20,607”

State corporate practice of medicine legislation

Oregon adopted legislation restricting corporate ownership of physician practices; proposals pending federally and in other states

96%
Source evidence
“proposed legislation in the Federal legislature and certain states, and adopted legislation in the state of Oregon, would limit, restrict, or prohibit corporate entities from owning or managing physician practices”

Data privacy regulation (GDPR and US laws)

Subject to GDPR and US state/federal health information privacy laws

95%
Source evidence
“satisfy legal or regulatory requirements, including the EU general data protection regulation (GDPR) and those related to patient-identifiable health information”

Healthcare fraud and abuse regulatory framework

Subject to Anti-Kickback Statute, Stark Law, False Claims Act; Medicare/Medicaid/340B participation; DOJ/FDA/DEA/FTC investigations possible

95%
Source evidence
“we are subject to extensive U.S. federal healthcare fraud and abuse laws, including the federal Anti-Kickback Statute, the federal self-referral law commonly known as the Stark Law and the federal False Claims Act.”

Sales and credit concentration risk

Significant customer loss, reduced purchases, or payment default risk

98%
Source evidence
“If CVS or another significant customer reduces their purchases from us, defaults in payment to us, does not renew or terminates their agreements, whether due to an alleged default by us or otherwise, our results of operations and financial condition could be adversely affected.”

MSO business strategy risks

MSO businesses face fraud/abuse laws and corporate-ownership legislation risks

97%
Source evidence
“risks arising under or related to fraud, waste, and abuse laws, including the federal Anti-Kickback Statute, the federal self-referral law commonly known as the Stark Law and the federal False Claims Act”

Cybersecurity risk

Material cyber-attack risk including incremental MSO cyber risk and rising insurance cost

96%
Source evidence
“companies in the healthcare industry are increasingly targeted for cyberattacks.”

Acquisition integration risk

Acquisition completion and integration risks could impact strategic objectives

94%
Source evidence
“future developments may impair the value of our purchased goodwill or intangible assets or may otherwise negatively affect our ability to achieve the financial, strategic, or other benefits we expect from the acquisitions.”

Anti-bribery / export control / FCPA exposure

Global operations subject to FCPA, U.K. Bribery Act, export controls and trade embargo laws

93%
Source evidence
“Our global operations are subject to the U.S. Foreign Corrupt Practices Act ("FCPA"), the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions, and U.S. and foreign export control, trade embargo, and customs laws.”

Single-source manufacturing dependency

Key products/components may be made at a single manufacturing facility with limited alternate facilities

93%
Source evidence
“any key products or components that is manufactured at a single manufacturing facility where there are limited alternate facilities.”

ERP implementation and business process risk

New ERP implementation and supply chain optimization initiatives in process

92%
Source evidence
“we are currently in the process of implementing a number of new Enterprise Resource Planning technologies across our organization.”

Weather and catastrophic event exposure

Weather-related property damage and transportation disruption; pandemics, sanctions, tariffs

92%
Source evidence
“our properties have experienced physical damage resulting from adverse or extreme weather resulting in costs for repairs and may cause disruptions or changes in operations. Additionally, storms have negatively impacted our transportation network, resulting in delivery delays or disruptions.”

Interest rate sensitivity

50 bps move = $14M interest expense / $19M interest income impact

92%
Source evidence
“At June 30, 2026, a hypothetical increase or decrease of 50 basis points in interest rates would result in an increase or decrease in interest expense of $14 million, respectively.”

Data and AI-dependent competitiveness

Competition increasingly dependent on data access/interpretation, including AI/ML systems

90%
Source evidence
“Our ability to compete effectively is increasingly dependent on access to and interpretation of data”

Material exposure graph

Healthcare
Revenue Exposure

Entire business is healthcare distribution and products; US healthcare environment shifts (value-based payments, shift out of hospitals) affect demand.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“Changes to the U.S. healthcare environment may not be favorable to us.”
CVS Health
Customer Exposure

CVS Health represented 28% of fiscal 2026 revenue and 22% of gross trade receivables, creating significant sales and credit concentration.

Relevance 95·Dependency 90·Confidence 99
Source evidence
“In fiscal 2026, CVS Health was our largest customer. CVS Health accounted for 28 percent of our fiscal 2026 revenue and 22 percent of our gross trade receivable balance at June 30, 2026.”
Hospitals, pharmacies, and other healthcare providers
Revenue Exposure

Revenue is generated from distribution to healthcare provider customers across hospital, pharmacy, lab, and office settings.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices”
National opioid litigation settlements (NOSA)
Legal Exposure

$4.3B accrued at June 30, 2026 with payments through 2038; FY2026 payments $417M and annual NOSA payments ($366M in FY2026, $374M in July 2026) represent a material multi-year cash obligation.

Relevance 92·Dependency 85·Confidence 96
Source evidence
“We have $4.3 billion accrued at June 30, 2026 related to certain national opioid litigation settlements”
Hospitals, healthcare systems, ambulatory surgery centers, clinical labs, physician offices
Customer Exposure

Pharma and GMPD segments distribute products and services to hospitals, healthcare systems, ambulatory surgery centers, clinical laboratories, and physician offices in the US and Canada.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada”
Pharmaceutical manufacturers
Supplier Dependency

The Pharma segment distributes products on behalf of pharmaceutical manufacturers and provides services to them, making manufacturers key supply partners for distribution revenue.

Relevance 88·Dependency 82·Confidence 90
Source evidence
“This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products”
Retail pharmacies (chain and independent drug stores, supermarket/mass merchandiser pharmacy departments)
Customer Exposure

Pharmaceutical Distribution delivers branded, generic, and OTC products to retail pharmacy customers under prime vendor relationships.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“distributes branded and generic pharmaceutical and over-the-counter healthcare and consumer products to retailers (including chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers), hospitals, and other healthcare providers”
Specialty pharmaceutical products
Revenue Exposure

Specialty businesses distribute specialty pharmaceuticals (oncology, rheumatology, etc.) and human-derived plasma products and support physician practices via MSO platforms, a key growth business within the Pharma segment.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“distributes specialty pharmaceutical products to hospitals, specialty pharmacies, and other healthcare providers and provides consulting, patient support, and other services for specialty pharmaceutical products to pharmaceutical manufacturers and healthcare providers”
Cybersecurity
Technology Dependency

Business relies on secure transmission/storage of patient-identifiable health and financial information; healthcare companies increasingly targeted; MSO adds incremental cyber risk.

Relevance 85·Dependency 80·Confidence 94
Source evidence
“Our business relies on the secure transmission, storage, and hosting of patient-identifiable health information, financial information, and other sensitive protected information”
Pharmaceutical manufacturers
Customer Exposure

Manufacturer services (distribution, inventory management, data reporting, new product launch support, chargeback administration) and branded distribution services fees tied to WAC are key revenue sources.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“provides services to pharmaceutical manufacturers, including distribution, inventory management, data reporting, new product launch support, and chargeback administration”
Corporate practice of medicine laws
Regulatory Exposure

Adopted Oregon legislation and proposed federal/state laws could restrict Cardinal Health's MSO ownership and management of physician practices, impacting the MSO strategy.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“If these regulations are ultimately adopted in other states in which we operate or plan to operate, our ability to continue to own these businesses in certain jurisdictions would be impacted.”
CVS Health Corporation
Supplier Dependency

Red Oak Sourcing, a 50/50-style sourcing venture with CVS Health through June 2029, negotiates generic pharmaceutical supply contracts for both companies, linking Cardinal Health's generics economics to this partnership.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health, negotiates generic pharmaceutical supply contracts on behalf of both companies. The term of Red Oak Sourcing extends through June 2029.”
MSO (management services organization) platforms
Technology Dependency

Pharma segment includes MSO platforms for physician offices; expanded via the ~$1.9B Solaris Health urology MSO acquisition, a strategic growth area.

Relevance 82·Dependency 70·Confidence 90
Source evidence
“we, through The Specialty Alliance, completed the acquisition of Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash”
Anti-Kickback Statute, Stark Law, False Claims Act
Legal Exposure

MSO businesses face risks under fraud, waste, and abuse laws including the federal Anti-Kickback Statute, Stark Law, and False Claims Act.

Relevance 80·Dependency 70·Confidence 94
Source evidence
“risks arising under or related to fraud, waste, and abuse laws, including the federal Anti-Kickback Statute, the federal self-referral law commonly known as the Stark Law and the federal False Claims Act”
Medicare / Medicaid / 340B
Regulatory Exposure

Some businesses are Medicare-certified suppliers or participate in Medicaid and 340B; noncompliance could cost program participation.

Relevance 80·Dependency 60·Confidence 92
Source evidence
“Some of our businesses are Medicare-certified suppliers or participate in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program.”
Anti-Kickback Statute / False Claims Act
Legal Exposure

DOJ CID under these statutes tied to a 2022 GPO/rheumatology MSO transaction.

Relevance 75·Dependency 50·Confidence 94
Source evidence
“focused on potential violations of the Anti-Kickback Statute and False Claims Act in connection with a 2022 transaction”
Enterprise Resource Planning (ERP) technologies
Technology Dependency

Ongoing ERP implementation, supply chain optimization, and AI/ML initiatives; failures could negatively impact business and internal control over financial reporting.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“if our relationship with critical third-party service providers deteriorates, we could experience negative impacts on our business, financial results, and our internal control over financial reporting.”
Single-source manufacturing facilities
Manufacturing Dependency

Key products or components manufactured at a single facility with limited alternates create manufacturing disruption risk.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“any key products or components that is manufactured at a single manufacturing facility where there are limited alternate facilities.”
IRS
Tax Exposure

IRS NOPAs could add up to roughly $1.8-2.0B including the $400M expense item, affecting effective tax rate and cash flow.

Relevance 70·Dependency 50·Confidence 93
Source evidence
“If the IRS prevails in one or both of these matters, the assessed tax would impact our financial results, effective tax rate, and cash flow.”
EU GDPR and US health information privacy laws
Regulatory Exposure

A cybersecurity incident could result in violations of GDPR and US state/federal patient data laws, leading to fines, litigation, and loss of customers.

Relevance 65·Dependency 60·Confidence 92
Source evidence
“result in a violation of these and other applicable laws and result in a loss of customers and revenues, remediation and other costs, increased insurance premiums, litigation, monetary fines and penalties”
Interest rates / financing cost
Cost Driver

Net interest expense rose from $51M (FY2024) to $348M (FY2026) alongside higher debt and cash payments for interest of $406M.

Relevance 65·Dependency 60·Confidence 90
Source evidence
“Interest expense, net348 215 51”
euro
Currency Exposure

Euro listed among principal drivers of FX exposure; transactional VAR $15M and translational VAR $2M for the upcoming fiscal year.

Relevance 65·Dependency 55·Confidence 95
Source evidence
“The following foreign currencies represent the principal drivers of our foreign exchange exposure: Canadian dollar, euro, Thai baht, Mexican peso, Chinese renminbi, Australian dollar, British pound, Japanese yen”
oil-based resins
Raw Material Dependency

GMPD's Cardinal Health branded products depend on commodities bought at market or index-linked prices; $457M forecasted exposure with $46M impact from a 10% move.

Relevance 60·Dependency 60·Confidence 90
Source evidence
“We are directly exposed to market price changes for certain commodities, including oil-based resins, nitrile, cotton, diesel fuel, and latex.”
Extreme weather and catastrophic events
Geopolitical Exposure

Extreme weather has damaged properties and disrupted the transportation network causing delivery delays; geopolitical events, trade sanctions, and tariffs also affect operations.

Relevance 60·Dependency 55·Confidence 90
Source evidence
“storms have negatively impacted our transportation network, resulting in delivery delays or disruptions.”
EtO/PFA emission regulations
Cost Driver

Tighter EtO/PFA sterilization emission standards could raise compliance costs and cause supply shortages or reduced surgical procedures.

Relevance 60·Dependency 50·Confidence 90
Source evidence
“If such measures become more widespread, we could experience increased costs to comply with reduced emissions standards and it is possible that we and other industry participants may be unable to effectively sterilize medical products.”
geopolitical_risk
Demand Driver

Commodity price fluctuation during fiscal 2026 attributed in part to the conflict in Iran, affecting Cardinal Health's raw material costs.

Relevance 55·Dependency 50·Confidence 85
Source evidence
“During fiscal 2026, the prices of certain commodities continued to experience fluctuation due in part to the conflict in Iran.”
Full company information
Latest profile, trading, valuation, and identifier data stored for CAH.
Share price
$253.77
Market cap
$58.76B
Exchange
NYSE
Currency
USD
CEO
Jason Hollar
Employees
61,344
IPO date
04/08/1983
Beta
0.521
Last dividend
$0.00
Day range
$252.91 – $253.77
52-week range
$180.45 – $259.84
1-day performance
-0.22%
1-year performance
40.63%
Current drawdown (1Y)
-2.34%
CIK
0000721371
CUSIP
14149Y108
ISIN
US14149Y1082
Created
07/12/2025, 03:10:40
Last update
03/11/2026, 15:31:13

Track Cardinal Health, Inc. with an AI analyst

See which prediction-market events move CAH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to CAH from your Railway `news_articles` table.

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Zacks Investment Research • STOCK • 12/06/2026, 12:41:11

Here's Why Cardinal Health (CAH) is a Strong Value Stock

Zacks Investment Research • STOCK • 01/06/2026, 12:42:35

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

Zacks Investment Research • STOCK • 27/05/2026, 14:11:13

Is Cardinal (CAH) a Buy as Wall Street Analysts Look Optimistic?

Zacks Investment Research • STOCK • 27/05/2026, 12:30:34

Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?

Zacks Investment Research • STOCK • 25/05/2026, 14:16:05

Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research • STOCK • 25/05/2026, 12:51:14

Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now

Zacks Investment Research • STOCK • 20/05/2026, 17:35:24

3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)

Zacks Investment Research • STOCK • 20/05/2026, 15:45:14

Is CAH Becoming the Backbone of US Healthcare Infrastructure?

Zacks Investment Research • STOCK • 19/05/2026, 17:30:50

CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?

Zacks Investment Research • STOCK • 14/05/2026, 16:10:41

Cardinal Health, Inc. (CAH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 18:10:45

Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?

Zacks Investment Research • STOCK • 13/05/2026, 13:40:45